Please login to the form below

RoActemra

This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

The EMA has laid out monitoring and mitigation strategies for these side effects, including the use of Roche’s RoActemra to treat CRS.

Latest news

Roche's Actemra/RoActemra receives new European approval

GCA is a chronic and potentially life-threatening autoimmune condition and Actemra/RoActemra’s approval was based on data from the phase III GiACTA study. ... As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to
Ocrevus off to a flying start as Roche raises 2017 forecasts

Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks
Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Sarilumab is a fully human monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6 receptors, and is the first direct competitor to Roche's Actemra/RoActemra (tocilizumab)
Manufacturing issues scupper Sanofi's sarilumab launch plans

Any delay to the programme is however a blow to Sanofi and Regeneron, which are playing catch-up against the only marketed IL-6 inhibitor - Roche's Actemra/RoActemra (tocilizumab) - while
Roche snags pair of FDA breakthrough designations

Meanwhile, Roche's interleukin-6 inhibitor RoActemra/Actemra (tocilizumab) picked up a BTD for giant cell arteritis, a chronic and potentially life-threatening autoimmune condition in which serious inflammation is seen

More from news
Approximately 5 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Achieving remission

Campaign:RoACTEMRA / ACTEMRA: beyond the boundaries of existing treatments. Timescale:2008 to 2009. ... Online monitoring tools tracked RoACTEMRA / ACTEMRA noise, identifed top influencers and tonality of digital conversations.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market
Brand leaders in RA will lose market share, predict rheumatologists

leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Medical Writer: Up to £50, 000 with Benefits

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Medical Writer: Great salary and benefits

Digital Account Director: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Project Manager/ Account Manager: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...